Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

Previous studies have identified Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP) as the predominant pathogens responsible for ventilator-associated pneumonia (VAP). The challenge of drug resistance, especially against carbapenem is intensifying, with variations noted across different regions. Multidrug-resistant organisms associated VAP (MDR-VAP) are increasing in frequency and are associated with significant morbidity, mortality, therefore imposes a heavy burden on the healthcare system. Colistin methanesulfonate sodium (CMS) has shown effectiveness against gram-negative bacteria, including carbapenem-resistant organisms (CRO) such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Klebsiella pneumoniae (CRKP). This trial aims to evaluate the efficacy of a 3-day course of inhaled CMS in lowering the incidence of VAP among patients undergoing invasive mechanical ventilation for at least two days and at high risk of MDR-VAP.

开始日期2025-04-01

申办/合作机构

山东大学齐鲁医院

NCT06907069

/ Enrolling by invitation临床4期IIT

A Multicenter, Prospective, Open-label Clinical Study on the Treatment of Carbapenem Resistant Gram-negative Bacterial Lung Infection With Sodium Polycolistin E Mesylate Intravenically Combined With Atomization

Pulmonary infection is a kind of infectious disease that seriously damages human health. It usually starts quickly and progresses rapidly in clinical manifestations, and is often accompanied by upper respiratory tract infection symptoms. With the increasing use of broad-spectrum antibiotics in clinical practice, the failure of anti-infection caused by drug-resistant bacteria is more and more common. Once a patient develops carbapenem-resistant gram-negative bacteria (CRO) infection, there are limited drug options. Therefore, HAP, as a serious and common complication, has a high incidence and mortality for ICU patients. In this study, patients who met the diagnostic criteria for pulmonary infection caused by CRO that was clearly or strongly suspected to be resistant to carbapenems but sensitive to CMS were selected, and the combined treatment regimen of CMS intravenous atomization was adopted. To explore the therapeutic effect of CMS combined with intravenous atomization in patients with carbapenem resistant gram-negative bacteria in lung infection. To evaluate the safety and tolerability of the combination regimen in patients with pulmonary infections caused by CRO. The purpose of this study was to explore the efficacy and safety of CMS combined with intravenous atomization in the treatment of patients with CRO induced pulmonary infection, and to provide a basis for its clinical rational application.

开始日期2025-01-01

申办/合作机构

宁波大学

CTRI/2024/12/077762

/ Not yet recruitingN/A

A prospective, non-randomized Population Pharmacokinetic study of Colistin in critically ill patients - NIL

开始日期2024-12-25

申办/合作机构

Post Graduate Institute of Medical Education & Research

100 项与多黏菌素E甲磺酸钠相关的临床结果

登录后查看更多信息

100 项与多黏菌素E甲磺酸钠相关的转化医学

登录后查看更多信息

100 项与多黏菌素E甲磺酸钠相关的专利（医药）

登录后查看更多信息

1,308

项与多黏菌素E甲磺酸钠相关的文献（医药）

2025-06-01·Environmental Research

Novel chitosan-magnetite-silica ternary capsules for highly efficient sequestration of reactive dyes from aqueous media

Article

作者: Bambal, Apurva ; Sarvanan, D ; Gaydhane, Arpita ; Chute, Anjali ; Jugade, Ravin

The main goal of this study was to synthesize novel Chitosan Magnetite Silica (CMS) adsorbent capsules and apply them for effective sequestration of anionic dyes Remazol brilliant blue 19 (RB-19) and Remazol golden yellow G -17 (RY-17) dye. The CMS capsules were synthesized and applied for batch study and evaluated using statistical modelling. Various analytical techniques, such as Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD), Thermogravimetry-Differential Thermal Analysis (TG-DTA), Brunauer-Emmett-Teller (BET) surface area analysis, UV-Vis Spectrophotometry, and Vibrating Sample Magnetometry (VSM), were employed to validate the formation of the CMS. Rough surface as shown by SEM analysis, presence of various functional groups as shown by FT-IR spectrum and presence Fe atoms in EDX spectrum are indication of formation of complete composite. The surface area of CMS recorded by BJH method was 39.05 m² g^-1 with pore capacity 0.259 cm³ g^-1. According to IUPAC classification, class IV isotherm was observed for nitrogen adsorption-desorption curves. The specific magnetization of CMS was 4.28 emu g^-1 indicating fare degree of magnetism making it easily separable using external magnet. Batch trails as well as screening experiments were conducted for the sequestration of RB and RY dyes. Dose 50 mg, interface time 60 min and solution pH of 3.0 depicted maximum removal efficacy of more than 95 % in both dyes even at high initial concentration of 200 mg L^-1. The adsorption capacities for RB-19 dye and RY-17 dye were found to be 455.86 and 344.06 mg g^-1 respectively in accordance with pseudo second order kinetics (R² = 0.997 and 0.962 respectively) and Langmuir adsorption isotherm (R² = 0.972 and 0.992 respectively) models. Six adsorption-desorption cycles were conducted for regeneration potential of CMS showcasing repeated usability after regeneration in alkaline medium. E-factor value of 0.04 depicted CMS capsules was sustainable in and eco-friendly with low waste generation.

2025-04-01·Biopharmaceutics & Drug Disposition

Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects

Article

作者: Hayashi, Yuto ; Yamada, Kohei ; Uchida, Atsushi ; Kihara, Tsubasa ; Sato, Hideyuki ; Onoue, Satomi

ABSTRACTThe present study aimed to develop a novel colon‐targeting microsphere of beclomethasone dipropionate (cMS/BDP) with enhanced pharmacological effect of BDP in the colon. cMS/BDP was prepared using Eudragit® S‐100 by the emulsion solvent diffusion method, and its physicochemical properties were characterized. A pharmacokinetic study was conducted to assess systemic exposure and colon distribution of BDP after oral administration of cMS/BDP to rats. A pharmacodynamic study was carried out to evaluate the anti‐inflammatory effect of cMS/BDP after its oral administration to ulcerative colitis model rats. The particle size of cMS/BDP was calculated to be ca. 20 μm, and most BDP in cMS/BDP might be in an amorphous state. In dissolution tests, cMS/BDP showed pH‐dependent release behavior of BDP and marked BDP release at pH 7.4. After oral administration of cMS/BDP (5 mg‐BDP/kg) to rats, BDP was rapidly metabolized to beclomethasone 17‐monopropionate (17‐BMP, a BDP metabolite) in the gastrointestinal tract and liver, and relative oral bioavailability of 17‐BMP in the cMS/BDP group was calculated to be ca. 4.8% compared with that in the BDP solution group. The tissue‐to‐plasma partition coefficient value, an index of colon distribution, for cMS/BDP was found to be 15‐fold higher than that for BDP solution. In the cMS/BDP (50 μg/kg) group, colonic myeloperoxidase activity and hyperplasia of the submucosa were negligibly elevated. From these findings, the cMS approach for BDP would be a promising dosage option for strategic colon delivery, leading to an improved therapeutic potential of BDP with a wide safety margin.

2025-03-07·Journal of Proteome Research

Heterogeneities of Site-Specific N-Glycosylation in the Hippocampus of Depression-like Behavior Models in Mice Induced by Acute Stress and Chronic Stress

Article

作者: Lyu, Boqiang ; Zhu, Jie ; Fu, Longhui ; Jia, Li ; Sun, Shisheng ; Gong, Xiaojuan ; Wang, Mengke ; Xu, Zongben ; Zhang, Siyuan ; Zhao, Na ; Ren, Pengyu

It is well established that acute and chronic stress contributes to the onset and progression of depression, but the underlying mechanisms have not been elucidated. Here an integrated N-glycoproteomic and proteomic analysis was performed to investigate heterogeneities of glycoprotein and site-specific glycosylation between the hippocampi of control, acute stress-affected (AS), and chronic mild stress-affected (CMS) mice. 1063 unique intact N-glycopeptides, 116 N-glycan compositions, and 512 glycosylation sites were identified. CMS and AS had significant effects on glycosylation. CMS reduced multiantenna glycosylation (N8H8 and N6H5F1S1) more strongly, while AS reduced multiantenna glycosylation (N5H3F1) more strongly. CMS inhibited high-mannose synthesis with high polymerization (N2H9 and N2H8), while AS inhibited high-mannose synthesis with low polymerization (N2H6, H2H5). Furthermore, 26 and 39 glycosylation-related genes (GRGs) were identified in the AS and CMS groups, separately. Functional enrichment analysis for GRGs in the AS and CMS groups exhibited that the up-regulated functions were leading edge membrane and cell adhesion molecule binding; meanwhile, the down-regulated functions were cAMP signaling pathways. Finally, tSNE analysis based on ScRNA-seq revealed that core GRGs were highly expressed in astrocytes. All of these findings improve our understanding of glycosylation in stress-related depression, providing valuable data resources for depression pathogenesis exploration and novel therapeutic target discovery.

项与多黏菌素E甲磺酸钠相关的新闻（医药）

2025-03-03

·正大天晴药业集团

月度盘点 | 正大天晴2月要闻回顾

过去的一个月正大天晴发生了哪些新鲜事让我们一起来回顾一下吧 #1 国产首创突破！妥洛特罗贴剂（德瑞妥）获批上市，守护全年龄段呼吸疾病患者健康 2月7日，北京泰德制药研发的妥洛特罗贴剂（商标名：德瑞妥）获得国家药品监督管理局颁发的上市批件，是首个获批上市的国产妥洛特罗贴剂。这款创新贴剂，通过透皮给药系统实现药剂缓释，即可在“晨降”高危时段持续舒张支气管，降低夜间发病风险。正大天晴将携手北京泰德制药保证该产品供应，守护全年龄段呼吸疾病患者健康。（点击此处跳转至原链接） #2 正大天晴国内率先完成等效性研究，乌美溴铵维兰特罗吸入粉雾剂上市申请获受理 2月9日，正大天晴开发的乌美溴铵维兰特罗吸入粉雾剂上市申请获CDE受理，适用于慢性阻塞性肺疾病（COPD）的长期维持治疗，有望为国内超1亿慢阻肺病患者提供新的治疗选择。正大天晴作为国内首家完成双支扩粉雾剂等效性研究的医药企业，此次申报进程的推进将进一步巩固公司在呼吸系统疾病治疗领域的领先地位。（点击此处跳转至原链接） #3 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足中国生物制药董事会主席谢其润获选“2024彭博《商业周刊》年度人物50”。2月14日，《商业周刊》发表了题为《中国生物制药董事会主席谢其润：只有创新才能在全球医药竞争中立足》的专访文章。（点击此处跳转至原链接） #4 纳入国家优化创新药临床试验审评试点项目，正大天晴1类新药研发提速 2月11日，正大天晴申报的1类创新药TQB2210临床试验申请获国家药监局药品审评中心（CDE）受理。作为公司首个纳入《优化创新药临床试验审评审批试点工作方案》的试点项目，TQB2210临床试验审评周期将缩短50%以上，从而有望更快惠及肿瘤患者。近年来，企业通过研发投入与政策借力，实现创新药管线的爆发式增长。（点击此处跳转至原链接） #5 安罗替尼“再挑战”研究入选2025 ESMO SRCC小型口头报告盐酸安罗替尼关于晚期软组织肉瘤（STS）的多中心回顾性研究，入选2025年欧洲肿瘤内科学会肉瘤及罕见肿瘤大会（ESMO SRCC）小型口头报告（Mini Oral）。该研究聚焦于安罗替尼“再挑战”既往治疗发生进展STS患者的疗效与安全性，将于3月20日至22日在瑞士卢加诺举行的大会上展示最新研究数据。（点击此处跳转至原链接） #6 南京市委书记周红波会见谢承润：支持打造百亿级链主企业共建生物医药创新发展高地 2月19日，南京市委书记周红波会见中国生物制药首席执行长、正大天晴董事长谢承润一行。（点击此处跳转至原链接） #7 《新华日报》头版头条文章点赞正大天晴 2月20日，《新华日报》头版头条发表文章《其命维新，稳步走好“第一方阵”》，对2024年江苏因地制宜发展新质生产力，“创新江苏”多项指标全国居首，进行了深度报道。其中，正大天晴聚焦国际前沿靶点，在肿瘤、肝病、呼吸等重点治疗领域创新药物研发成果斐然受到关注。（点击此处跳转至原链接） #8 当选上海生物医药商会副会长谢承润:以“创新”“国际化”为战略双翼构建全球化产业协同体系 2月22日，上海市工商联生物医药商会第一届一次会员会议暨生物医药发展大会举行。上海市副市长刘多、陈宇剑，市政协副主席、市工商联主席寿子琪，中国药学会理事长孙咸泽出席。当选副会长的中国生物制药首席执行长、正大天晴董事长谢承润受邀参加“创新与出海”圆桌会，表示将以“数字化赋能”与“生态链协同”推动创新突破与国际化布局，与行业伙伴携手推动中国医药从“跟随”到“引领”的跨越。（点击此处跳转至原链接） #9 正大天晴“靶免联合”新突破，肺巨细胞癌患者无进展生存期达30个月 1类创新药安罗替尼联合派安普利单抗治疗晚期肺巨细胞癌的罕见病例报道，在医学期刊《Frontiers in Oncology》上发表，成功帮助一名晚期肺巨细胞癌伴脑转移、PD-L1高表达和TP53突变患者实现无进展生存30个月，为罕见肺癌治疗提供了新的思路和希望。（点击此处跳转至原链接） #10 “天韵”破局！新研究为血液病合并脓毒症治疗提供关键证据当地时间2月23日至25日，一项关于多黏菌素E甲磺酸钠（商标名：天韵）治疗血液病合并脓毒症的研究在美国重症医学会年会（SCCM 2025）以口头报告的形式公布，为破解这一困局提供了关键证据。（点击此处跳转至原链接） #11 关注罕见病，让生命不因“罕见”而孤独全球3.5亿罕见病患者中，中国有近2000万患者在与命运抗争。正大天晴2款在研的重磅产品正致力于攻克《罕见病目录》中的治疗难题。《罕见病目录》之外，正大天晴还有4款1类新药，正在向发病率极低的国际罕见病种发起挑战。（点击此处跳转至原链接）注：以上内容根据本公众号发稿时间统计。声明：本文的著作权由原作者或本公司享有，未经授权，不得以转载、复制、摄制、改编、汇编等方式使用。文中出现的人物肖像，其肖像权归本人所有，未经授权，禁止使用。 ● 月度盘点 | 正大天晴12月要闻回顾 ● 月度盘点 | 正大天晴11月要闻回顾 ● 月度盘点 | 正大天晴10月要闻回顾

上市批准申请上市

2025-02-26

·正大天晴药业集团

“天韵”破局！新研究为血液病合并脓毒症治疗提供关键证据

有研究表明，近三成血液病患者在治疗的第一年里因严重感染而发生脓毒症[1]，其中碳青霉烯类耐药病原菌（CRO）感染所致的脓毒症病死率高、危害大，成为临床医生面临的重大挑战[2]。当地时间2月23日至25日，一项关于多黏菌素E甲磺酸钠（商标名：天韵）治疗血液病合并脓毒症的研究在美国重症医学会年会（SCCM 2025）以口头报告的形式公布，为破解这一困局提供了关键证据。该研究回顾性分析了多黏菌素E甲磺酸钠在真实世界中治疗中国血液病合并脓毒症患者的有效性和安全性，旨在为多黏菌素E甲磺酸钠的临床应用提供更多证据，实现血液病患者脓毒症的精准治疗。研究聚焦81例确诊脓毒症的血液病患者，其中白血病患者占66.67%，其次为淋巴瘤、再生障碍性贫血，32.1%的患者曾接受异基因造血干细胞移植，72.84%的患者在感染开始时发生中性粒细胞减少。研究结果表明，在采用多黏菌素E甲磺酸钠治疗后，患者的临床有效率为62.96%，微生物清除率为59.26%，ICU和总住院时间的中位数分别为13.5天和33天[3]。值得注意的是，血液病患者通常有严重的基础疾病并伴有其他肾毒性药物治疗，因此关注多黏菌素E甲磺酸钠肾毒性尤为重要。此次研究中，纳入的患者均被诊断为脓毒症，使用多黏菌素E甲磺酸钠后感染得到控制，18.5%的患者出现肾功能不全的不良反应，无永久性肾功能丧失病例发生[3]。多黏菌素E甲磺酸钠（商标名：天韵）由正大天晴开发，于2021年10月获批上市，斩获国内首仿。血液病患者作为多重耐药细菌尤其是碳青霉烯类耐药革兰阴性菌感染的高危群体，其脓毒症病死率居高不下，含多黏菌素E甲磺酸钠的联合抗感染治疗方案为此类患者的临床救治提供了新的参考。参考文献： [1] MacPhail A, Dendle C, Slavin M, Weinkove R, Bailey M, Pilcher D, et al. Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study. Crit Care. 2024;28(1):148. [2] Hansen BA, et al. Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis. 2020;12(1):e2020009. [3] Xie Yan, Fu jianhong, et al. COLISTIN IS EFFICACIOUS AND SAFE FOR THEMANAGEMENT OF SEPSIS IN HEMATOLOGICAL DISEASESPATIENTS. Critical care Medicine 53(1): january 2025. 声明： 1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2. 本公司不对任何药品和/或适应症作推荐。 3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。 ● 当选上海生物医药商会副会长谢承润:以“创新”“国际化”为战略双翼构建全球化产业协同体系 ● 南京市委书记周红波会见谢承润：支持打造百亿级链主企业共建生物医药创新发展高地 ● 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足 ● 正大天晴“靶免联合”新突破，肺巨细胞癌患者无进展生存期达30个月

临床研究上市批准微生物疗法

2025-02-18

·正大天晴

就在本周！广谱抗生素新成果将在美国重症医学会年会口头汇报

当地时间2月23日至25日，第54届美国重症医学会年会（2025 SCCM）将在奥兰多举行。中国生物制药（1177.HK）下属企业正大天晴将以口头报告的形式，公布多黏菌素E甲磺酸钠治疗血液病伴脓毒症的最新研究成果，让中国方案惠及全球患者。耐药革兰阴性菌感染是血液病患者入住重症监护室（ICU）和死亡的主要原因，多黏菌素作为治疗这类患者的“最后一道防线”，被视作临床上不可替代的核心药物[1,2]。耐药革兰阴性菌感染正迅速演变为全球公共卫生领域的重大威胁，特别是多次化疗或造血干细胞移植后粒细胞缺乏患者容易合并多重耐药菌感染。由于其多重耐药性，临床治疗选择有限，致使患者病死率居高不下。多黏菌素E甲磺酸钠作为治疗多重耐药铜绿假单胞菌、鲍曼不动杆菌等革兰阴性菌的“最后防线”，因其耐药率低于5%且无交叉耐药性，成为重症感染救治的核心药物[3,4]。正大天晴于2021年10月国内首仿获批多黏菌素E甲磺酸钠（商标名：天韵），填补了这类药物的国产空白。由于多黏菌素E甲磺酸钠在我国上市较晚，目前基于中国人群的循证证据有限，尤其是在血液病患者脓毒症的治疗方面还缺乏有说服力的研究成果。此次将在SCCM年会展示的研究成果，回顾性分析了多黏菌素E甲磺酸钠在真实世界中治疗中国血液病合并脓毒症患者的有效性和安全性，旨在为该类抗生素的临床应用提供更多证据，实现血液病患者脓毒症的精准治疗。参考文献： [1] ARDEBILI A,IZANLOO A,RASTEGAR M.Polymyxin combination therapy for multidrug-resistant,extensively-drug resistant,and dificult-to-treat drug-resistant Gram-negative infections:is it superior to polymyxin mono-therapy?[J].Expert Rev Anti Infect Ther,2023,21(4):387-429. [2] Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study.J Clin Oncol.2013;31(22):2810-2818. [3] Tsuji BT et al. International Consensus Guidelines for the Optimal Use of the Polymyxins:Endorsed by the American College of Clinical Pharmacy(ACCP), European Society of Clinical Microbiology and Infectious Diseases(ESCMID), Infectious Diseases Society of America(IDSA), International Society for Antiinfective Pharmacology(ISAP), Society of Critical Care Medicine(SCCM), and Society of Infectious Diseases Pharmacists(SIDP).Pharmacotherapy.2019 Jan;39(1):10-39. [4] 胡付品,等.CHINET 2024年上半年细菌耐药监测结果. 声明： 1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2. 本公司不对任何药品和/或适应症作推荐。 3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。前瞻性声明：本新闻稿中包含若干前瞻性陈述，包括有关【多黏菌素E甲磺酸钠（商标名：天韵）】的临床开发计划、临床获益与优势的预期、商业化展望、患者临床获益可能性，以及潜在商业机会等声明。“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“有望”、“打算”、“计划”、“潜在”、“预测”、“预计”、“应该”、“将”、“拟”、“会”和类似表达旨在识别前瞻性陈述，但并非所有前瞻性陈述都包含这些识别词。这些前瞻性陈述为公司基于当前所掌握的数据和信息所做的预测或期望，可能因受到政策、研发、市场及监管等不确定因素或风险的影响，而导致实际结果与前瞻性陈述有重大差异。请现有或潜在的投资者审慎考虑可能存在的风险，并不可完全依赖本新闻稿中的前瞻性陈述，该等陈述包含信息仅及于本新闻稿发布当日。除非法律要求，本公司无义务因新信息、未来事件或其他情况而对本新闻稿中任何前瞻性陈述进行更新或修改。

临床研究

100 项与多黏菌素E甲磺酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02049	多黏菌素E甲磺酸钠	J01XB01 A07AA10	DB01111

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
革兰氏阴性菌感染	中国	正大天晴药业集团股份有限公司	2021-10-11
肺部感染	列支敦士登	Essential Pharma Ltd.	2012-02-13
肺部感染	欧盟	Essential Pharma Ltd.	2012-02-13
肺部感染	挪威	Essential Pharma Ltd.	2012-02-13
肺部感染	冰岛	Essential Pharma Ltd.	2012-02-13
囊性纤维化	澳大利亚	Phebra Pty Ltd.	2011-02-02
铜绿假单胞菌感染	澳大利亚	Phebra Pty Ltd.	2011-02-02
感染	美国	Endo Operations Ltd.	1970-06-04
感染性肠炎	日本	Sun Pharma Japan Ltd.	1960-11-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
囊性纤维化	临床3期	瑞士	Spexis Ltd.	-
非囊性支气管扩张	临床2期	西班牙	Zambon SpA	2017-06-06
支气管扩张	临床2期	以色列	Zambon SpA	2017-06-01
支气管扩张	临床2期	荷兰	Zambon SpA	2017-06-01
支气管扩张	临床2期	德国	Zambon SpA	2017-06-01
支气管扩张	临床2期	比利时	Zambon SpA	2017-06-01
支气管扩张	临床2期	西班牙	Zambon SpA	2017-06-01
支气管扩张	临床2期	英国	Zambon SpA	2017-06-01
支气管扩张	临床2期	新西兰	Zambon SpA	2017-06-01
非囊性支气管扩张	临床前	西班牙	Zambon SpA	2017-06-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03460704 (PROMIS-II, CTgov)	临床3期	非囊性支气管扩张 \| 慢性肺疾病	287	CMS (CMS (Colistimethate Sodium))	衊鬱願積鹽繭網鬱構簾(鹽積糧醖鹹鑰廠鑰範願) = 獵鏇鹹夢積構餘齋遞選網餘製築窪淵齋憲築齋 (窪網壓鏇廠淵衊遞壓襯, 獵顧獵壓壓襯鹽壓夢艱 ~ 齋糧壓選醖遞簾齋製鏇)	-	2023-12-29
				Placebo (Placebo)	衊鬱願積鹽繭網鬱構簾(鹽積糧醖鹹鑰廠鑰範願) = 範膚積遞衊壓廠糧襯鬱網餘製築窪淵齋憲築齋 (窪網壓鏇廠淵衊遞壓襯, 襯繭襯遞蓋鑰餘窪簾選 ~ 積鏇窪艱夢積窪遞餘網)
#4733 (ERA2023)	N/A	-	148	COLISTIN (Nephrotoxicity group)	艱糧築鑰淵構築範壓選(膚淵蓋繭夢築壓構網蓋) = 築觸窪廠獵衊淵範襯憲鏇製簾壓窪遞蓋製鏇範 (齋鬱顧夢襯顧鹽餘衊憲 ) 更多	不佳	2023-06-14
NCT03093974 (PROMIS-I, Corporate Publications) 人工标引	临床3期	非囊性支气管扩张	377	Colistimethate Sodium	(顧襯願構鹹憲夢蓋觸窪) = 艱淵糧糧簾鏇築淵鬱獵醖繭鹹遞蓋餘淵齋積襯 (選鹹築鏇艱艱襯廠繭衊 )	积极	2021-09-08
				Placebo	(顧襯願構鹹憲夢蓋觸窪) = 壓願窪遞遞蓋鏇顧鬱憲醖繭鹹遞蓋餘淵齋積襯 (選鹹築鏇艱艱襯廠繭衊 )
ASN2017	N/A	急性肾损伤	126	Colistimethate Sodium	艱衊艱艱遞願襯遞鹹憲(憲顧鏇積製壓壓膚壓獵) = 顧鹽衊遞壓夢繭壓獵鏇遞憲製夢淵衊餘衊襯醖 (廠鹽鏇襯糧簾獵網衊衊 )	积极	2017-10-31
ERS2017	N/A	Pseudomonas aeruginosa	-	Tobramycin	糧夢膚憲顧選網餘淵齋(餘衊積獵積齋鏇顧鑰構) = 醖糧糧齋製鏇衊網襯獵網選艱簾選膚壓蓋膚選 (獵衊淵鹽鑰蓋蓋廠醖襯 ) 更多	-	2017-09-01
				Colistimethate sodium	糧夢膚憲顧選網餘淵齋(餘衊積獵積齋鏇顧鑰構) = 齋蓋鬱顧壓餘遞衊鏇觸網選艱簾選膚壓蓋膚選 (獵衊淵鹽鑰蓋蓋廠醖襯 ) 更多
ISRCTN49790596 (Pubmed \| Am J Respir Crit Care Med)	N/A	铜绿假单胞菌感染	-	Colistin	繭廠鏇獵衊壓鏇糧遞顧(遞顧襯鹹製鏇鹽顧窪製) = 簾糧鏇艱鬱範製鏇餘淵衊衊鑰艱鬱願襯憲鬱鏇 (膚夢衊衊膚鹽網願夢鏇 )	积极	2014-04-15
				Placebo	繭廠鏇獵衊壓鏇糧遞顧(遞顧襯鹹製鏇鹽顧窪製) = 鑰遞襯願網壓淵鹹鹽廠衊衊鑰艱鬱願襯憲鬱鏇 (膚夢衊衊膚鹽網願夢鏇 )
AAAAI2014	N/A	-	-	Colistimethate Sodium (More aggressive desensitization protocol)	簾構襯窪簾鬱遞衊憲顧(廠壓窪鏇選壓獵襯窪蓋) = 願範積膚範膚鑰築選鹹願範積壓壓衊願鏇憲製 (夢積餘膚衊製夢鹽鬱顧 )	-	2014-02-01
ERS2013	N/A	医院获得性肺炎 \| 肾脏毒性	97	Colomycin	(膚鬱襯衊範鬱齋蓋獵壓) = 壓願遞網衊鬱構顧選醖選製鬱構積衊艱鹹觸壓 (衊繭繭鏇襯蓋糧齋製廠, 10 ~ 141) 更多	-	2013-09-01
				Colimycin	(膚鬱襯衊範鬱齋蓋獵壓) = 鏇窪鏇膚衊鏇簾顧繭鏇選製鬱構積衊艱鹹觸壓 (衊繭繭鏇襯蓋糧齋製廠, 10 ~ 141) 更多
NCT01449838 (Pubmed \| Curr Med Res Opin)	临床1期	-	22	Colistin methanesulfonate sodium	醖廠願繭醖糧鑰築觸築(鹹顧夢齋積餘製鹹蓋蓋) = resulted in transient increase of urinary N-acetyl-β-D-glucosaminidase (NAG) and protein 淵築壓淵醖獵鏇廠憲構 (觸獵齋齋選襯夢鑰顧鬱 ) 更多	-	2011-12-01